The invention presents macroporous cryogel matrices designed to enhance gene delivery, particularly lentiviral gene delivery to immune cells. By crosslinking the polymer matrix with another polymer or modifying it with polypeptides, these matrices offer a promising avenue for improving the efficiency and efficacy of gene therapy. The methods for producing these matrices and their compositions further contribute to advancing gene delivery technologies.
Figure (1) Schematic representation of virus retention, cell attachment and subsequent transduction on PEGDA, PEGDA–GELMA and PEGDA–PLL cryogel matrices.
Current gene delivery methods, especially those involving cytotherapy and adoptive T cell therapy, encounter challenges related to the persistence, engraftment, and effector functions of ex vivo modified cells. Additionally, virus-based gene delivery, while effective, poses concerns regarding immunogenicity and long-term effects. Furthermore, existing materials for gene delivery, such as PLGA scaffolds, suffer from immunogenicity issues.
- The use of cryogelation to produce macroporous structures allows for efficient in vivo recruitment and transduction of cells.
- PEGDA-based matrices are less immunogenic compared to traditional PLGA scaffolds.
- Modifying the matrices with polypeptides like PLL enhances cell adhesion and virus retention, improving the efficiency of gene delivery.
- The matrices eliminate the need for harsh organic solvents in their preparation, making the process safer and more environmentally friendly.
This patent can revolutionize gene therapy and cell-based treatments by offering a safer, more effective way to deliver genes. It enables precise, localized gene delivery, crucial for advancing cancer immunotherapies and regenerative medicine. By reducing systemic side effects and improving treatment efficacy, it promises to make gene therapies more successful and accessible for a range of diseases, ultimately enhancing public health and quality of life.
Through in vitro virus release, cell transduction, and in vivo gene delivery experiments, efficient and localized lentiviral gene delivery via covalently modified virus-laden PEGDA–PLL cryogels has been demonstrated. This method has shown efficacy compared to traditional bolus injection of viruses, indicating its potential as a superior gene delivery approach.
4
This patent can revolutionize gene therapy and cell-based treatments by offering a safer, more effective way to deliver genes. It enables precise, localized gene delivery, crucial for advancing cancer immunotherapies and regenerative medicine. By reducing systemic side effects and improving treatment efficacy, it promises to make gene therapies more successful and accessible for a range of diseases, ultimately enhancing public health and quality of life.
Biotechnology, pharmaceuticals, healthcare, research and development, biomedical engineering, and regenerative medicine.
Geography of IP
Type of IP
201921038250
457682